Paras Healthcare Limited
NSE: PARASHLTH
Business score
How strong the business is, in one number. The parts behind it are in Pro.
No business score for this company yet.
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹7,498 Cr
P/E ratio
171.0
P/B ratio
—
ROCE
14.0%
ROE
13.0%
Dividend yield
—
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Not enough price history yet.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
No answers for this company yet.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
3 of 6 checks clear · 50%
3 of 9 checks could not be run.
Latest result
What the last results showed. Whether management kept its word is in Pro.
Results are expected soon.
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹7,498 Cr
- Prev close
- —
- 52w High
- —
- 52w Low
- —
- Enterprise value
- —
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 2.1%
- PEG ratio
- —
- P/E ratio
- 171.0
- P/B ratio
- —
- EV / EBITDA
- —
- Industry P/E
- —
- ROCE
- 14.0%
- ROCE 5y average
- 9.3%
- ROE
- 13.0%
- Debt / Equity
- 3.5
- Interest coverage
- 1.6
- Dividend yield
- —
- ROE 3y average
- -4.0%
- ROE last year
- 13.0%
Annual P&L
- Annual revenue
- ₹1,606 Cr
- Annual profit
- ₹44.0 Cr
- Operating margin
- 20.0%
- Net profit margin
- 2.7%
- EBITDA margin
- 19.7%
- Sales growth 3y
- 20.5%
- Sales growth 5y
- —
- Profit growth 3y
- 45.0%
- Profit growth 5y
- —
- EPS
- ₹4.3
- Sales growth TTM
- 24.0%
- Profit growth TTM
- 175.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- —
- Profit latest quarter
- —
- YoY quarterly sales growth
- —
- YoY quarterly profit growth
- —
- OPM latest quarter
- —
Balance Sheet
- Book Value
- ₹39.5
- Face Value
- ₹1.0
- Total debt
- ₹1,394 Cr
- Total cash
- ₹303 Cr
- Borrowings
- ₹1,394 Cr
- Reserves / Equity
- 38.5
Cash Flow
- Operating cash flow
- ₹164 Cr
- Free cash flow
- -₹5.00 Cr
- FCF yield
- -1.7%
- Net cash flow
- ₹10.0 Cr
Shareholding
- Promoter holding
- 68.0%
- FII holding
- —
- DII holding
- —
- Public holding
- —
Peer comparison
| Company | P/E | Mkt cap ₹ Cr | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|
| Jio Platformsas of 28 Oct 2026 | 34.2 | 10.30L | 7,764 | 39,173 | 12.08% | ||
| EAAA Indiaas of 28 Oct 2026 | 39.4 | 10,765 | 125 | 414 | 26.58% | ||
| Paras Healthcare | 171.0 | 7,498 | 14.00% | ||||
| SFC Enviro.as of 28 Oct 2026 | 20.9 | 3,233 | 1.48 | 215.27% | 134 | 97.58% | 24.06% |
| BLS Polymersas of 28 Oct 2026 | 34.5 | 930 | 30.21% | ||||
| M. K. Sons Fineas of 28 Oct 2026 | 17.6 | 912 | 36.83% | ||||
| Bombay Coatedas of 28 Oct 2026 | 18.0 | 515 | 20.51% | ||||
| Medianas of 28 Oct 2026 | 19.8 | 390 | 6.05 | 113.29% | 69.9 | 48.79% | 30.21% |
Competes with: Apollo Hospitals, Jio Platforms Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
This company does not publish this table.
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 918 | 1,129 | 1,294 | 1,606 |
| Expenses | 846 | 994 | 1,155 | 1,290 |
| Operating Profit | 71 | 135 | 139 | 316 |
| OPM % | 8.00% | 12.00% | 11.00% | 20.00% |
| Other Income | 18 | 22 | 20 | 23 |
| Interest | 51 | 69 | 94 | 119 |
| Depreciation | 65 | 81 | 116 | 144 |
| Profit before tax | -27 | 7 | -50 | 76 |
| Tax % | 58.00% | 331.00% | 16.00% | 42.00% |
| Net Profit | -43 | -15 | -58 | 44 |
| EPS in Rs | -4.38 | -1.57 | -5.94 | 4.34 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- 20%
- TTM
- 24%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 45%
- TTM
- 175%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- -4%
- Last year
- 13%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 10 |
| Reserves | 26 | 329 | 271 | 385 |
| Borrowings | 756 | 548 | 728 | 1,394 |
| Other Liabilities | 507 | 592 | 802 | 282 |
| Total Liabilities | 1,293 | 1,478 | 1,810 | 2,071 |
| Fixed Assets | 780 | 988 | 1,173 | 1,211 |
| CWIP | 78 | 29 | 38 | 29 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 435 | 461 | 599 | 832 |
| Total Assets | 1,293 | 1,478 | 1,810 | 2,071 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from Operating Activity | 44 | 92 | 86 | 164 |
| Cash from Investing Activity | -126 | -194 | -147 | -239 |
| Cash from Financing Activity | 97 | 94 | 83 | 86 |
| Net Cash Flow | 15 | -8 | 22 | 10 |
| Free Cash Flow | -69 | -102 | -49 | -5 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 106 | 76 | 69 | 69 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 52 | 51 | 66 | 79 |
| Inventory Days | 27 | 34 | 28 | 27 |
| Days Payable | 191 | 169 | 206 | 177 |
| Cash Conversion Cycle | -112 | -84 | -112 | -70 |
| Working Capital Days | -184 | -67 | -87 | -56 |
| ROCE % | 9.00% | 5.00% | 14.00% |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
No brick chart yet.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
Capex
Capex (fiscal year)
₹169 Cr
2026-03-31
Capex to revenue (fiscal year)
10.52%
2026-03-31
News
News and filings about Paras Healthcare Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare - Hospitals
- Industry
- Classification
- Healthcare - Hospitals
- ISIN
- INE661T01029
News impact
Big market events that reach Paras Healthcare Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
No dividends, splits or big trades on record.
Documents
Annual reports, results presentations and earnings calls, straight from the source.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.